VIRMA and central nervous system cancer: In this study, two glioma subgroups were identified based on the expression of m6A regulators, and a risk signature (ALKBH5, IGF2BP3, KIAA1429, and YTHDF2) was significantly associated with prognosis, the immune microenvironment and treatment efficacy [101].